The quarter came in modestly ahead of published expectations. Revenue was $4.983 billion versus published estimates of roughly $4.89–$4.94 billion, while adjusted diluted EPS was $3.23 versus roughly $3.13–$3.17 expected. That is a real beat, but not a large one. Revenue grew 4.4% organically after adjusting for currency, led by Interventional at 5.5% and BioPharma Systems at 5.2% (Financial Highlights; Segment revenues).
| Metric | Q3 FY2026 | Q3 FY2025 | Change / expectation |
|---|---|---|---|
| Revenue | $4.983B | $4.726B | +5.4% reported; +4.4% FX-neutral (Financial Highlights) |
| Adjusted diluted EPS | $3.23 | $3.08 | +4.9%; above published ~$3.13–$3.17 consensus |
| Reported diluted EPS from continuing operations | $1.64 | $1.57 | +4.5% (Financial Highlights) |
| Free cash flow, nine months | $1.728B | $1.195B | +44.6% (Cash Flow reconciliation) |
| FY2026 adjusted EPS guidance | $12.62–$12.72 | $11.90 FY2025 | Prior range: $12.52–$12.72 (Guidance table) |
The more important forward-looking change was a modest guidance upgrade. BD left revenue growth unchanged at low-single-digit-plus reported and low-single-digit FX-neutral, but raised the bottom of its adjusted EPS range by $0.10 and the midpoint by $0.05 (Guidance table). That suggests management is gaining some confidence in earnings delivery, but the unchanged revenue outlook limits the size of the positive revision.
Cash generation was materially better, while reported profitability remains noisy. Continuing operating cash flow rose to $2.104 billion from $1.578 billion and free cash flow reached $1.728 billion (Cash Flow statement; Free Cash Flow reconciliation). However, quarterly operating income fell 10.3% to $663 million as total operating costs rose 8.4%, faster than revenue (Income Statement). The nine-month adjusted EPS figure was still down 0.7% year over year, so the quarter's improvement does not yet represent a broad acceleration in the full-year earnings trend (Nine-Month Adjusted EPS reconciliation).
The net read is a narrow positive rather than a major reset. BD delivered a small revenue and adjusted-EPS beat, raised the EPS guidance floor, and showed strong cash conversion. Against that, organic growth is only moderate, international FX-neutral revenue was essentially flat at 0.6%, and the full-year revenue outlook was unchanged (Geographic revenue table; Guidance table). The filing therefore improves the near-term picture versus expectations, but only incrementally.
Read the original 8-K on SEC EDGAR ↗